


numares' New Multicenter Study PARASOL: Metabolic Constellations across Europe

5 European sites, 4 metabolic biomarkers and 1 aim: Support a physician's diagnosis to potentially reduce the number of unpleasant kidney biopsies: The pan-European multicenter study PARASOL utilizes numares' proprietary *Magnetic Group Signaling (MGS®)* technology based on nuclear magnetic resonance (NMR) spectroscopy. PARASOL was preceded by the UMBRELLA study, in which the initial mathematical model for the presented test was developed.

The prospective PARASOL study will enroll at least 1,000 patients across the continent. Metabolic constellations are evaluated to detect the risk of acute allograft rejection in spot urine samples. This is achieved with numares' *AXINON® renalTX-SCORE®-U100** which is a non-invasive, CE-marked in-vitro diagnostic test (IVD) for the diagnosis of kidney transplant rejection. First results of this study are expected in 4Q2018. □

Simone Mark, Clinical Development
Julia Hertlein, Marketing



* For Research Use only in the United States. numares' products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.